MCID: VSC003
MIFTS: 55

Visceral Leishmaniasis

Categories: Bone diseases, Gastrointestinal diseases, Immune diseases, Infectious diseases

Aliases & Classifications for Visceral Leishmaniasis

MalaCards integrated aliases for Visceral Leishmaniasis:

Name: Visceral Leishmaniasis 12 15 17 32
Leishmaniasis, Visceral 43 71
Infection by Visceral Leishmaniasis 12
Leishmaniasis Visceral 54
Kala-Azar 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9146
ICD9CM 34 085.0
MeSH 43 D007898
NCIt 49 C34771
SNOMED-CT 67 186803007
ICD10 32 B55.0
UMLS 71 C0023290

Summaries for Visceral Leishmaniasis

Disease Ontology : 12 A leishmaniasis that is the most severe form of the disease caused by protozoan parasites of the Leishmania genus, resulting in the infection of the internal organs such as liver, spleen and bone marrow. The symptoms include fever, weight loss, and an enlarged spleen and liver.

MalaCards based summary : Visceral Leishmaniasis, also known as leishmaniasis, visceral, is related to hemophagocytic lymphohistiocytosis and human immunodeficiency virus type 1. An important gene associated with Visceral Leishmaniasis is LMLN (Leishmanolysin Like Peptidase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Lidocaine and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 74 Visceral leishmaniasis (VL), also known as kala-azar, is the most severe form of leishmaniasis and,... more...

Related Diseases for Visceral Leishmaniasis

Diseases related to Visceral Leishmaniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 900)
# Related Disease Score Top Affiliating Genes
1 hemophagocytic lymphohistiocytosis 31.5 TNF IL18 IL10 IFNG CXCL8
2 human immunodeficiency virus type 1 31.4 TNF LTA IL2 IL10 IFNG
3 scleritis 31.2 TNF IL4 IFNG
4 epidemic typhus 31.2 TLR4 TLR2 IL10
5 leishmaniasis 31.1 TNF TLR9 TLR4 TLR2 SLC11A1 PGD
6 purpura 31.1 TNF IL4 IL10 IFNG
7 noma 31.1 IL18 CXCL8 ALB
8 miliary tuberculosis 31.1 TNF IFNG ALB
9 sleeping sickness 31.1 PGD NOS2 LMLN IL10
10 syphilis 31.0 TNF IFNG ALB
11 cryoglobulinemia 31.0 TNF IL1B IL10 IFNG
12 acquired immunodeficiency syndrome 31.0 TNF NOS2 IL2 IL1B IL10 IFNG
13 tuberculoid leprosy 31.0 TLR2 IL2 IL10 IFNG
14 lymphopenia 31.0 IL4 IL2 IL18 IL10 IFNG FOXP3
15 portal hypertension 31.0 TNF TLR4 NOS2 CXCL8 ALB
16 neutropenia 31.0 TNF TLR4 IL2 IL1B IL10 IFNG
17 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.9 IL10 IFNG FOXP3
18 pancreatitis 30.9 TNF IL1B IL10 ALB
19 autoimmune hepatitis 30.9 TNF IL4 IL10 FOXP3 ALB
20 glomerulonephritis 30.9 TLR9 NOS2 IL1B ALB
21 human immunodeficiency virus infectious disease 30.9 TNF TLR9 IL4 IL2 IL10 IFNG
22 autoimmune vasculitis 30.9 TNF IL4 IL2 IL1B
23 trichinosis 30.9 IL4 IL13 IL10
24 blepharitis 30.9 TNF IL4 IL1B
25 poliomyelitis 30.8 TNF IL4 IL10 IFNG
26 keratoconjunctivitis sicca 30.8 TNF IL4 ALB
27 alopecia 30.8 TNF IL4 IL2 IL1B IFNG
28 intestinal schistosomiasis 30.8 IL4 IL13 IL10
29 hemolytic anemia 30.8 TNF IL4 IL2 IL10 IFNG
30 mucocutaneous leishmaniasis 30.8 TNF LMLN IL4 IL2 IL13 IL10
31 echinococcosis 30.8 TNF TLR4 TLR2 IL10 IFNG
32 keratitis, hereditary 30.8 TNF TLR4 TLR2 IL1B
33 schistosomiasis 30.7 TNF IL4 IL2 IL13 IL10 IFNG
34 lichen planus 30.7 TNF TLR2 IL4 IL2 IL10 IFNG
35 melioidosis 30.7 TNF TLR4 TLR2 IL18 IL10 IFNG
36 cytomegalovirus retinitis 30.7 TNF IL10 IFNG
37 severe combined immunodeficiency 30.7 IL4 IL2 IL13 IL10 IFNG
38 hypersplenism 30.7 TLR4 LTA IL4 IFNG FOXP3 ALB
39 b-cell growth factor 30.7 IL4 IFNG
40 influenza 30.6 TNF TLR4 IL1B IFNG CXCL8
41 mixed connective tissue disease 30.6 TNF IL10 IFNG
42 acute pancreatitis 30.6 TNF TLR4 IL1B IL18 IL10 CXCL8
43 hepatitis b 30.6 TNF TLR4 TLR2 IFNG CXCL8 ALB
44 acute kidney tubular necrosis 30.6 TNF IL18 ALB
45 fatty liver disease 30.6 TNF TLR4 IL1B CXCL8 ALB
46 post-transplant lymphoproliferative disease 30.6 TNF SLC11A1 LTA IL10
47 hepatic encephalopathy 30.6 TNF IL18 ALB
48 tuberculous meningitis 30.6 TNF TLR2 CXCL8
49 adult-onset still's disease 30.6 TNF IL1B IL18 CXCL8
50 bronchopneumonia 30.5 TNF TLR4 IL1B IL10 CXCL8 ALB

Graphical network of the top 20 diseases related to Visceral Leishmaniasis:



Diseases related to Visceral Leishmaniasis

Symptoms & Phenotypes for Visceral Leishmaniasis

GenomeRNAi Phenotypes related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

26 (show all 29)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.1 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.1 HSPA4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-108 10.1 HSPA4
4 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.1 IL13
5 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.1 IL10
6 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.1 IL10
7 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.1 HSPA4 TLR4
8 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.1 IL10
9 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.1 IL10
10 Increased shRNA abundance (Z-score > 2) GR00366-A-165 10.1 IL13
11 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.1 HSPA4
12 Increased shRNA abundance (Z-score > 2) GR00366-A-181 10.1 IL13
13 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.1 IL10
14 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.1 IL13
15 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.1 IL10
16 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.1 IL10
17 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.1 TLR4
18 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.1 IL10
19 Increased shRNA abundance (Z-score > 2) GR00366-A-53 10.1 IL10
20 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.1 IL13
21 Increased shRNA abundance (Z-score > 2) GR00366-A-65 10.1 IL10
22 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.1 IL10
23 Increased shRNA abundance (Z-score > 2) GR00366-A-68 10.1 IL10 TLR4
24 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.1 IL10
25 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.1 IL10
26 Increased shRNA abundance (Z-score > 2) GR00366-A-89 10.1 HSPA4
27 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.53 CXCL8 IL10 IL18 IL1B LTA NOS2
28 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.53 CXCL8 IL10 IL18 IL1B IL2 LTA
29 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.53 NOS2

MGI Mouse Phenotypes related to Visceral Leishmaniasis:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.44 ALB FOXP3 HSPA4 IFNG IL10 IL13
2 immune system MP:0005387 10.43 ALB FOXP3 IFNG IL10 IL13 IL18
3 digestive/alimentary MP:0005381 10.42 ALB FOXP3 IFNG IL10 IL13 IL18
4 hematopoietic system MP:0005397 10.42 FOXP3 IFNG IL10 IL13 IL18 IL1B
5 homeostasis/metabolism MP:0005376 10.41 ALB FOXP3 IFNG IL10 IL13 IL18
6 mortality/aging MP:0010768 10.41 ALB FOXP3 HSPA4 IFNG IL10 IL13
7 cardiovascular system MP:0005385 10.38 ALB FOXP3 IFNG IL10 IL18 IL1B
8 growth/size/body region MP:0005378 10.37 FOXP3 IFNG IL10 IL13 IL18 IL1B
9 endocrine/exocrine gland MP:0005379 10.35 ALB FOXP3 HSPA4 IFNG IL10 IL13
10 integument MP:0010771 10.25 FOXP3 IFNG IL10 IL13 IL18 IL1B
11 liver/biliary system MP:0005370 10.24 ALB FOXP3 IFNG IL10 IL2 IL4
12 nervous system MP:0003631 10.18 HSPA4 IFNG IL10 IL13 IL18 IL1B
13 craniofacial MP:0005382 10.13 FOXP3 IFNG IL10 IL1B IL4 NOS2
14 neoplasm MP:0002006 10.13 ALB IFNG IL10 IL1B IL2 NOS2
15 muscle MP:0005369 10.11 ALB IFNG IL10 IL13 IL18 NOS2
16 reproductive system MP:0005389 9.96 FOXP3 HSPA4 IFNG IL10 IL13 IL2
17 renal/urinary system MP:0005367 9.92 ALB FOXP3 IFNG IL4 NOS2 TLR2
18 no phenotypic analysis MP:0003012 9.91 FOXP3 IFNG IL10 IL13 IL2 IL4
19 respiratory system MP:0005388 9.9 FOXP3 IFNG IL10 IL13 IL2 IL4
20 skeleton MP:0005390 9.7 IFNG IL10 IL13 IL1B IL4 LTA
21 vision/eye MP:0005391 9.32 FOXP3 IFNG IL10 IL18 IL2 IL4

Drugs & Therapeutics for Visceral Leishmaniasis

Drugs for Visceral Leishmaniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
3
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
4
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965 14956
5
Dimethyl sulfoxide Approved, Vet_approved Phase 4 67-68-5 679
6
deoxycholic acid Approved Phase 4 83-44-3 222528
7
meglumine antimoniate Experimental, Investigational Phase 4 133-51-7
8 Anthelmintics Phase 4
9 Antimony Sodium Gluconate Phase 4
10 Anesthetics Phase 4
11 Antifungal Agents Phase 4
12 Liposomal amphotericin B Phase 4
13 Amebicides Phase 4
14 Anti-Bacterial Agents Phase 4
15 Gastrointestinal Agents Phase 4
16 Amphotericin B, deoxycholate drug combination Phase 4
17
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
18
Pentamidine Approved, Investigational Phase 3 100-33-4 4735
19
Aluminum sulfate Approved Phase 2, Phase 3 10043-01-3
20
Miltefosine Approved, Investigational Phase 3 58066-85-6 3600
21
Paromomycin Approved, Investigational Phase 3 7542-37-2, 1263-89-4 165580
22
Nitric Oxide Approved Phase 3 10102-43-9 145068
23
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
24 Tocotrienol Investigational Phase 3 6829-55-6
25
BCG vaccine Investigational Phase 2, Phase 3
26 Vaccines Phase 2, Phase 3
27 Vitamins Phase 3
28 Tocotrienols Phase 3
29 Tocopherols Phase 3
30 Immunologic Factors Phase 2, Phase 3
31 Adjuvants, Immunologic Phase 2, Phase 3
32 Antiparasitic Agents Phase 3
33 Antiprotozoal Agents Phase 3
34 Anti-Infective Agents Phase 3
35 Respiratory System Agents Phase 3
36 Antioxidants Phase 3
37 Protective Agents Phase 3
38 Neurotransmitter Agents Phase 3
39 Anti-Asthmatic Agents Phase 3
40 Endothelium-Dependent Relaxing Factors Phase 3
41 Vasodilator Agents Phase 3
42 Bronchodilator Agents Phase 3
43 Pharmaceutical Solutions Phase 2
44 Fat Emulsions, Intravenous Phase 2
45 Soy Bean Phase 2
46 Soybean oil, phospholipid emulsion Phase 2
47 Parenteral Nutrition Solutions Phase 2
48 Thromboplastin Phase 1
49
Acetylcysteine Approved, Investigational 616-91-1 12035
50
Erythromycin Approved, Investigational, Vet_approved 114-07-8 12560 441411

Interventional clinical trials:

(show top 50) (show all 72)
# Name Status NCT ID Phase Drugs
1 Point of Care Diagnosis and Treatment With Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India. Unknown status NCT01566552 Phase 4 AMBISOME
2 Safety and Effectiveness of Short-course AmBisome in the Treatment of Post-Kala-azar Dermal Leishmaniasis (PKDL): a Prospective Cohort Study in Bangladesh Completed NCT03311607 Phase 4 AmBisome
3 A Phase 4 Study to Expand Access Program While Assessing the Safety and Efficacy of Paromomycin IM Injection in an Outpatient Setting for the Treatment of Visceral Leishmaniasis Completed NCT00604955 Phase 4 Paromomycin sulfate
4 A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) Completed NCT01975051 Phase 4 Mitefosine
5 Efficacy and Safety of Amphotericin B Deoxycholate Compared to Meglumine Antimoniate for Treatment of Visceral Leishmaniasis in Brazilian Children Completed NCT01032187 Phase 4 Meglumine antimoniate;Amphotericin B-deoxycholate
6 An Open Label Study of RFH Therapy as Treatment for CL Caused by Leishmania Tropica in India Completed NCT01661296 Phase 4 Sodium stibogluconate
7 Comparison of Effectiveness of Topical Amphotericin B in 30% Dimethylsulphoxide and 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis: Randomized Double Blind Controlled Trial Pilot Study Recruiting NCT03814343 Phase 4 amphotericin B in 30% DMSO;30% DMSO
8 Multicentric Efficacy and Safety Study of Antileishmanial Drugs for Treatment of Visceral Leishmaniasis in Brazil Terminated NCT01310738 Phase 4 Antimoniate of N-methylglucamine;amphotericin B deoxycholate;Liposomal amphotericin B;Liposomal amphotericin B;Antimoniate of N-methylglucamine
9 A Prospective, Multicentric, Randomized, Two Arm, Open Label Phase III Study To Assess Efficacy And Safety Of Infusion Of Amphomul® (Amphotericin B Emulsion) As Compared To Liposomal Amphotericin In Patients Of Visceral Leishmaniasis (Kala Azar) Completed NCT00876824 Phase 3 Amphotericin B Lipid emulsion;Liposomal Amphotericin B
10 A Multicentre Comparative Trial of Efficacy and Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) Versus Combination of SSG and PM as the First Line Treatment for Visceral Leishmaniasis in Ethiopia, Kenya and Sudan Completed NCT00255567 Phase 3 Sodium Stibogluconate;Paromomycin sulphate;SSG and Paromomycin sulphate
11 A Randomised, Open-label, Parallel-group, Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens (Co-administration), of AmBisome, Paromomycin and Miltefosine in Visceral Leishmaniasis (VL) Completed NCT00523965 Phase 3 amphotericin B deoxycholate;Liposomal Amphotericin B with Miltefosine;Liposomal Amphotericin B and Paromomycin Sulfate;miltefosine + Paromomycin sulfate
12 A Phase 3 Multicenter, Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Injectable Paromomycin in Patients With Visceral Leishmaniasis Completed NCT00216346 Phase 3 Paromomycin sulfate;Amphotericin B
13 A Study for Safety and Efficacy of Miltefosine for Treatment of Children and Adolescents With Post-Kala-azar Dermal Leishmaniasis (PKDL) in Bangladesh and Association of Serum Vitamin E and Exposure to Arsenic With PKDL Completed NCT02193022 Phase 3 Miltefosine
14 Replacement of Insecticides to Control Visceral Leishmaniasis Completed NCT01644682 Phase 3
15 A Phase III Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Single Infusion of Liposomal Amphotericin B in Patients With Visceral Leishmaniasis Completed NCT00628719 Phase 3 Liposomal Amphotericin B;amphotericin B deoxycholate
16 An Open Lable Randomised Two -Arm Study to Assess the Safety and Efficacy of Paromomycin Administered Intramuscularly at Two Different Dosing Regimens (14 Days Versus 21 Days) for the Treatment of Indian Visceral Leishmaniasis (VL) Completed NCT00629031 Phase 3 Paromomycin;Paromomycin
17 Randomized, Open-label, Parallel-group, Safety & Efficacy Study to Evaluate Different Combination Treatment Regimens, of Either AmBisome and Paromomycin, AmBisome and Miltefosine, or Paromomycin and Miltefosine Compared With Amphotericin B Deoxycholate (the Standard) Therapy for the Treatment of Acute, Symptomatic Visceral Leishmaniasis (VL). Completed NCT00696969 Phase 3 Amphotericin B Deoxycholate;Ambisome + Miltefosine;Ambisome and Paromomycin;Miltefosine and Paromomycin
18 A Phase III, Open Label, Randomised, Study of Three Short Course Combination Regimens (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome® Alone for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh Completed NCT01122771 Phase 3 Liposomal amphotericin B;liposomal amphotericin B + miltefosine;liposomal amphotericin B + paromomycin;Miltefosine + Paromomycin
19 A Randomized Trial of Ambisome Monotherapy and Combination of Ambisome and Miltefosine for the Treatment of VL in HIV Positive Patients in Ethiopia Followed by Secondary VL Prophylactic Treatment With Pentamidine. Completed NCT02011958 Phase 3 Liposomal Amphotericin B;Miltefosine
20 Secondary Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients Using Pentamidine as a Prophylactic Agent: a Prospective Cohort Study Completed NCT01360762 Phase 3 Pentamidine
21 Phase 3, Clinical Trials of Drug Against Cutaneous Leishmaniasis Completed NCT00351520 Phase 3 Miltefose
22 A Randomized, Safety, Immunogenicity & Efficacy Study of Autoclaved Leishmania Major Plus BCG vs. BCG (Double Blind) or Placebo (Open), in Healthy High Risk Iranian Volunteers With Positive Response to Leishmanin (LST>0) Completed NCT00429780 Phase 2, Phase 3
23 A Randomized, Safety, Immunogenicity & Efficacy Study of Autoclaved Leishmania Major Plus BCG vs. BCG (Double Blind) or Placebo (Open), in Healthy High Risk Iranian Volunteers With no Response to Leishmanin Completed NCT00429715 Phase 2, Phase 3
24 An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin With SSG and PM Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa Recruiting NCT03129646 Phase 3 Miltefosine;Paromomycin;Sodium stibogluconate
25 Double Blind, Randomized Controlled Trial, to Evaluate the Effectiveness of a Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Terminated NCT00317629 Phase 3 controlled nitric oxide releasing patch;meglumine antimoniate
26 A Prospective, Single Center, Open-Label, Dose-Escalation Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Treatment Naïve Or Resistant Cases Of Visceral Leishmaniasis (Kala-Azar). Completed NCT00497601 Phase 2 Amphotericin B fat emulsion in visceral leishmaniasis;Amphotericin B fat emulsion;Amphotericin B in fat emulsion
27 The Efficacy and Safety of a Short Course of Miltefosine and Liposomal Amphotericin B for Visceral Leishmaniasis in India Completed NCT00371995 Phase 2 Liposomal amphotericin B and Miltefosine
28 A Phase II, Multi-centre, Open-label, Randomised Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral Sitamaquine Compared With Amphotericin B in the Treatment of Visceral Leishmaniasis Caused by L. Donovani in Endemic Areas. Completed NCT00381394 Phase 2 sitamaquine
29 An Open-label Clinical Trial to Assess the Pharmacokinetics and Safety of Miltefosine Allometric Dose for the Treatment of Children With Primary Visceral Leishmaniasis in Eastern Africa Completed NCT02431143 Phase 2 Miltefosine
30 A Phase II Randomized, Parallel Arm, Open-labeled Clinical Trial to Assess the Safety and Efficacy of the Combination of Sodium Stibogluconate Plus Single Dose AmBisome®, Miltefosine Plus Single Dose AmBisome® and Miltefosine Alone for the Treatment of Primary Visceral Leishmaniasis in Eastern Africa Completed NCT01067443 Phase 2 Liposomal amphotericin B (AmBisome®) and sodium stibogluconate;Liposomal amphotericin B + miltefosine;Miltefosine
31 Combination Chemotherapy for the Treatment of Indian Visceral Leishmaniasis: Miltefosine Plus Liposomal Amphotericin B - Dose and Duration Ranging Study Completed NCT00370825 Phase 2 Combination therapy with AmBisome and miltefosine
32 A Phase IIa Safety Study to Assess the Safety and Immunogenicity of a New Leishmania Vaccine Candidate ChAd63-KH Completed NCT02894008 Phase 2 ChAd63-KH
33 Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL) Completed NCT01635777 Phase 2 Miltefosine;Miltefosine
34 Sodium Stibogluconate Treatment of Leishmaniasis Completed NCT00662012 Phase 2 Sodium Stibogluconate (SSG)
35 Department of Defense Protocol for the Use of Sodium Stibogluconate (Pentostam) as a Treatment for Leishmaniasis Completed NCT00657618 Phase 1, Phase 2 Sodium Stibogluconate (SSG)
36 A Randomized, Open Label, Multicenter Study to Determine the Efficacy and Safety of Combining Thermotherapy and a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨ Completed NCT02687971 Phase 2 Miltefosine
37 An Open Label, Randomized, Parallel Arm Clinical Trial of Two Regimens to Assess the Safety and Efficacy for Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) Patients in Sudan Recruiting NCT03399955 Phase 2 Paromomycin;Ambisome;Miltefosine
38 A Phase IIb Study to Assess the Safety, Efficacy and Immunogenicity of the Leishmania Vaccine ChAd63-KH in Post-kala Azar Dermal Leishmaniasis Recruiting NCT03969134 Phase 2
39 A Phase II Study to Assess the Safety and Efficacy of the Leishmania Vaccine ChAd63-KH for the Prevention of Post-kala Azar Dermal Leishmaniasis Not yet recruiting NCT04107961 Phase 2
40 Miltefosine for Brazilian Visceral Leishmaniasis Terminated NCT00378495 Phase 1, Phase 2 Miltefosine: initially 2.5 mg/kg/day for 28 days
41 Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With Visceral Leishmaniasis Terminated NCT00832208 Phase 2 Liposomal amphotericin B (Ambisome);Liposomal amphotericin B (Ambisome)
42 Phase II Proof of Concept Trial to Determine Efficacy of Fexinidazole in Visceral Leishmaniasis Patients in Sudan Terminated NCT01980199 Phase 2 Fexinidazole
43 A Phase I/II Clinical Trial To Assess the Safety and Biologic Activity of the Anti-IL-10 Monoclonal Antibody, SCH708980, in Combination With AmBisome(Registered Trademark), Versus That of Placebo in Combination With Ambisome(Registered Trademark), in Subjects With Visceral Leishmaniasis (VL) Withdrawn NCT01437020 Phase 1, Phase 2 SCH708980 Anti-IL-10 monoclonal;AmBisome
44 A Phase 1, Open-Label Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-F3 + SLA-SE Vaccine Compared to LEISH-F3 + GLA-SE Vaccine in Healthy Adult Subjects Completed NCT02071758 Phase 1
45 A Phase 1, Open-Label, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-111F + MPL-SE Vaccine (Recombinant Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE) in Healthy Adults In India Completed NCT00486382 Phase 1
46 Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine in Combination With SSG in the Treatment of Patients With PKDL Completed NCT00982774 Phase 1
47 Multi-Center, Open-Label, Randomized, Two Treatment, Parallel, Single Period, Multiple-Dose, Steady State, Global Bioequivalence Study of Amphotericin B Liposome for Injection 50mg /Vial in Patients With Visceral Leishmaniasis Completed NCT03636659 Phase 1 Amphotericin B Liposome;AmBisome (Amphotericin B) Liposome
48 A Phase 1, Randomized Clinical Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of The LEISH-F3 + GLA-SE Vaccine Compared To The LEISH-F3 Protein Alone In Healthy Adult Subjects Completed NCT01484548 Phase 1
49 A Phase I, Double-blind, Randomised, Single Centre, Parallel Group, Single-dose, Dose-escalation, Placebo Controlled Study of the Safety, Tolerability and Pharmacokinetics of DNDI-0690 After Oral Dosing in Healthy Male Subjects Recruiting NCT03929016 Phase 1 DNDI-0690;Placebo of DNDI-0690
50 Study for Evaluation of the Immune Response of Visceral Leishmaniasis Patients Treated With Antimonial Pentavalent Associated to N-Acetylcysteine Unknown status NCT01138956 N-acetylcysteine;Pentavalent antimonial

Search NIH Clinical Center for Visceral Leishmaniasis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Meglumine
Pentamidine
Pentamidine Isethionate

Cochrane evidence based reviews: leishmaniasis, visceral

Genetic Tests for Visceral Leishmaniasis

Anatomical Context for Visceral Leishmaniasis

MalaCards organs/tissues related to Visceral Leishmaniasis:

40
Testes, T Cells, Bone, Bone Marrow, Liver, Spleen, Skin

Publications for Visceral Leishmaniasis

Articles related to Visceral Leishmaniasis:

(show top 50) (show all 8283)
# Title Authors PMID Year
1
Plasma lipoproteins in visceral leishmaniasis and their effect on Leishmania-infected macrophages. 54 61
20398226 2010
2
Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis. 54 61
20404924 2010
3
Immunologic indicators of clinical progression during canine Leishmania infantum infection. 61 54
20032217 2010
4
Increased levels of IL-10, IL-12, and IFN- in patients with visceral leishmaniasis. 61 54
19578629 2009
5
In situ immune responses to interstitial pneumonitis in human visceral leishmaniasis. 61 54
19149777 2009
6
Leishmania donovani vs immunity: T-cells sensitized from Leishmania of one donor may modulate their cytokines pattern on re-stimulation with Leishmania from different donor in visceral leishmaniasis. 54 61
18948098 2009
7
IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. 54 61
17911647 2007
8
Interleukin-10 and the pathogenesis of human visceral leishmaniasis. 54 61
17689290 2007
9
Immunopathology of leishmaniasis: an update. 61 54
17880757 2007
10
Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. 54 61
17389235 2007
11
Cystatin C as a marker of immune complex-associated renal impairment in a Sudanese population with visceral leishmaniasis. 54 61
17123978 2006
12
Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alpha(+) monocytes are hallmarks of active human visceral Leishmaniasis due to Leishmania chagasi infection. 54 61
16968407 2006
13
Immunology of canine leishmaniasis. 54 61
16842269 2006
14
Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis. 61 54
16364177 2005
15
Leishmania donovani: effect of therapy on expression of CD2 antigen and secretion of macrophage migration inhibition factor by T-cells in patients with visceral leishmaniasis. 54 61
16023642 2005
16
Interleukin-12 augments a Th1-type immune response manifested as lymphocyte proliferation and interferon gamma production in Leishmania infantum-infected dogs. 54 61
15619517 2005
17
Elevated plasma levels of interferon (IFN)-gamma, IFN-gamma inducing cytokines, and IFN-gamma inducible CXC chemokines in visceral leishmaniasis. 61 54
15569785 2004
18
Adjunct effect of immunostimulating hexapeptide analogous to human beta-casein fragment (54-59) to sodium stibogluconate against experimental visceral leishmaniasis. 61 54
15518175 2004
19
Immunity and immunosuppression in experimental visceral leishmaniasis. 54 61
15064826 2004
20
Cellular profile of cytokine production in a patient with visceral leishmaniasis: gammadelta+ T cells express both type 1 cytokines and interleukin-10. 54 61
12641659 2003
21
Genetic control of visceral leishmaniasis in a Sudanese population: candidate gene testing indicates a linkage to the NRAMP1 region. 61 54
12618857 2003
22
Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. 61 54
12379707 2002
23
Reactive oxygen intermediates, nitrite and IFN-gamma in Indian visceral leishmaniasis. 54 61
11422203 2001
24
Tissue cytokine responses in canine visceral leishmaniasis. 61 54
11294678 2001
25
Association analysis of HLA-class II and class III gene polymorphisms in the susceptibility to mediterranean visceral leishmaniasis. 54 61
11334675 2001
26
Interleukin-13 in Iranian patients with visceral leishmaniasis: relationship to other Th2 and Th1 cytokines. 61 54
11280075 2001
27
IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. 61 54
10930301 2000
28
HIV-1 alters T helper cytokines, interleukin-12 and interleukin-18 responses to the protozoan parasite Leishmania donovani. 54 61
10853973 2000
29
Role of CD8+ T cells in endogenous interleukin-10 secretion associated with visceral leishmaniasis. 61 54
10733741 2000
30
A novel Leishmania infantum recombinant antigen which elicits interleukin 10 production by peripheral blood mononuclear cells of patients with visceral leishmaniasis. 54 61
10639426 2000
31
High levels of C-reactive protein in the peripheral blood during visceral leishmaniasis predict subsequent development of post kala-azar dermal leishmaniasis. 61 54
10708005 2000
32
Leishmania-specific T cells expressing interferon-gamma (IFN-gamma) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis. 61 54
10361241 1999
33
T cell response of asymptomatic Leishmania chagasi infected subjects to recombinant leishmania antigens. 54 61
10348984 1999
34
Increased levels of soluble interleukin-4 receptor in the sera of patients with visceral leishmaniasis. 61 54
9952391 1999
35
T-cell response in human leishmaniasis. 61 54
10065635 1999
36
Splenic cytokine responses in Indian kala-azar before and after treatment. 54 61
9498473 1998
37
Human_leishmaniasis/cytokines.bahia.br. 54 61
9686193 1998
38
Cytokine profile and pathology in human leishmaniasis. 61 54
9686192 1998
39
Presence of circulating levels of interferon-gamma, interleukin-10 and tumor necrosis factor-alpha in patients with visceral leishmaniasis. 61 54
9713135 1998
40
High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. 54 61
9472662 1998
41
Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. 54 61
9333181 1997
42
Protective effect of neoglycoprotein-conjugated muramyl dipeptide against Leishmania donovani infection: the role of cytokines. 61 54
9164956 1997
43
Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. 54 61
9180602 1997
44
Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model. 61 54
9120392 1997
45
Current and future clinical applications of interferon-gamma in host antimicrobial defense. 61 54
8923089 1996
46
Antimony/interferon-gamma combination in the treatment of visceral leishmaniasis in AIDS. 61 54
8874638 1996
47
Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis. 54 61
8648233 1996
48
Effect of treatment with interferon-gamma alone in visceral leishmaniasis. 61 54
7594733 1995
49
In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis. 61 54
8580385 1995
50
Treatment of visceral leishmaniasis in a patient with AIDS with antimony and gamma-interferon: remission and prevention of relapse by maintenance therapy with weekly pentamidine. 61 54
7566284 1995

Variations for Visceral Leishmaniasis

Expression for Visceral Leishmaniasis

Search GEO for disease gene expression data for Visceral Leishmaniasis.

Pathways for Visceral Leishmaniasis

Pathways related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 87)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.16 TNF TLR9 TLR4 TLR2 SLC11A1 NOS2
2
Show member pathways
13.92 TNF NOS2 LTA IL4 IL2 IL1B
3
Show member pathways
13.82 TNF TLR4 NOS2 LTA IL4 IL2
4
Show member pathways
13.67 TNF LTA IL4 IL2 IL1B IL18
5
Show member pathways
13.57 TNF TLR9 TLR4 TLR2 LTA IL4
6
Show member pathways
13.53 TNF NOS2 LTA IL4 IL2 IL1B
7
Show member pathways
13.44 TNF LTA IL4 IL2 IL1B IL18
8
Show member pathways
13.34 TNF TLR9 TLR4 TLR2 IL4 IL2
9
Show member pathways
13.24 TNF TLR9 TLR4 TLR2 NOS2 IL2
10
Show member pathways
13.01 TNF TLR9 TLR4 TLR2 IL2 IL1B
11
Show member pathways
12.99 TNF LTA IL4 IL2 IL1B IL13
12 12.95 NOS2 IL4 IL2 IL13 IFNG CXCL8
13 12.92 TNF TLR9 TLR2 LTA IL1B IFNG
14
Show member pathways
12.92 TNF TLR9 TLR4 TLR2 NOS2 IL1B
15
Show member pathways
12.88 TNF TLR9 TLR4 TLR2 LTA IL2
16
Show member pathways
12.8 TNF TLR9 TLR4 TLR2 IL4 IL2
17
Show member pathways
12.77 TNF IL4 IL2 IL18 IL10 IFNG
18
Show member pathways
12.77 TNF NOS2 IL2 IL1B IL18 IL10
19 12.76 TNF TLR9 TLR2 IL4 IL2 IL1B
20
Show member pathways
12.74 TNF TLR9 TLR4 TLR2 LTA IL1B
21
Show member pathways
12.6 TNF TLR4 TLR2 IL4 IL2 IL1B
22
Show member pathways
12.55 IL4 IL2 IL13 IL10 IFNG
23
Show member pathways
12.55 TNF TLR2 IL4 IL1B IL13 IFNG
24 12.53 TNF TLR4 IL1B IL18 CXCL8
25
Show member pathways
12.52 TNF LTA IL2 IL18 IL10 CXCL8
26 12.52 TNF TLR9 TLR4 TLR2 IL1B IL18
27
Show member pathways
12.51 TNF IL4 IL2 IL1B IFNG ALB
28
Show member pathways
12.49 TNF TLR4 NOS2 IL1B IFNG CXCL8
29
Show member pathways
12.46 TNF TLR4 TLR2 NOS2 IL4 IL1B
30
Show member pathways
12.43 TNF LTA IL4 IL2 IL1B IL18
31 12.42 TNF TLR4 IL1B IL18 CXCL8
32
Show member pathways
12.41 TNF TLR9 TLR4 TLR2 CXCL8
33 12.39 TNF TLR4 IL1B IL18 CXCL8
34 12.38 TNF TLR9 TLR4 TLR2 NOS2 IFNG
35
Show member pathways
12.37 TNF TLR9 IL2 IL1B IL10
36 12.33 TNF IL1B IL13 IL10 CXCL8
37 12.31 TNF TLR9 TLR4 TLR2 NOS2 IL1B
38
Show member pathways
12.29 TNF TLR4 IL1B IFNG
39
Show member pathways
12.25 TLR9 TLR4 TLR2 IL2 IL1B IL13
40
Show member pathways
12.24 TNF TLR9 TLR4 TLR2 NOS2 IL4
41 12.23 TNF TLR4 IL2 IL1B IL18 IL10
42 12.22 TNF TLR4 NOS2 IL4 IL2 IL1B
43
Show member pathways
12.2 NOS2 IL4 IL2 IL1B IL18 IFNG
44 12.18 TNF IL4 IL2 IL10 IFNG
45 12.15 TNF NOS2 IL4 IL1B IL18 IL13
46 12.12 TNF TLR4 LTA IL1B CXCL8
47
Show member pathways
12.09 TLR9 TLR4 TLR2 IL4 IL1B IFNG
48 12.09 TNF TLR4 TLR2 IL1B IL18 IFNG
49 12.09 TNF TLR4 TLR2 NOS2 IL1B IL10
50 12.01 TLR4 IL2 IL18 CXCL8

GO Terms for Visceral Leishmaniasis

Cellular components related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 TNF TLR9 LTA IL4 IL2 IL1B
2 extracellular space GO:0005615 9.36 TNF LTA IL4 IL2 IL1B IL18

Biological processes related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 108)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.4 TLR9 TLR4 TLR2 LTA IL4 IL1B
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.32 TNF TLR9 TLR4 TLR2 SLC11A1 IL4
3 negative regulation of cell proliferation GO:0008285 10.17 TLR2 IL1B IL10 FOXP3 CXCL8
4 defense response to bacterium GO:0042742 10.12 TNF TLR9 TLR4 SLC11A1 NOS2 IL10
5 cellular response to lipopolysaccharide GO:0071222 10.1 TNF TLR4 NOS2 IL1B IL10 CXCL8
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.1 TNF TLR9 TLR4 TLR2 IL1B IL18
7 cell-cell signaling GO:0007267 10.09 LTA IL2 IL1B IL18
8 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.06 TNF TLR9 TLR4 IL1B
9 positive regulation of protein phosphorylation GO:0001934 10.06 TNF IL2 IL1B IFNG
10 negative regulation of inflammatory response GO:0050728 10.06 IL4 IL2 IL13 IL10 FOXP3
11 cytokine-mediated signaling pathway GO:0019221 10.06 TNF NOS2 IL4 IL2 IL1B IL18
12 inflammatory response GO:0006954 10.02 TNF TLR9 TLR4 TLR2 SLC11A1 NOS2
13 defense response to Gram-negative bacterium GO:0050829 10.01 TLR9 TLR4 SLC11A1 NOS2
14 positive regulation of JNK cascade GO:0046330 10 TNF TLR9 TLR4 IL1B
15 positive regulation of interleukin-6 production GO:0032755 10 TNF TLR9 TLR4 TLR2 IL1B
16 positive regulation of gene expression GO:0010628 10 TNF TLR9 TLR4 TLR2 SLC11A1 IL4
17 regulation of insulin secretion GO:0050796 9.99 TNF NOS2 IL1B IFNG
18 positive regulation of interleukin-6 secretion GO:2000778 9.97 TNF TLR4 TLR2 IL1B IFNG
19 response to lipopolysaccharide GO:0032496 9.97 TLR4 TLR2 SLC11A1 NOS2 LTA IL1B
20 cellular response to mechanical stimulus GO:0071260 9.96 TLR4 IL1B IL13
21 positive regulation of phagocytosis GO:0050766 9.96 TNF SLC11A1 IL1B IFNG
22 cellular response to organic cyclic compound GO:0071407 9.95 TNF IL1B IL18
23 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.95 TNF TLR9 TLR4
24 positive regulation of nitric oxide biosynthetic process GO:0045429 9.95 TNF TLR4 IL1B IFNG
25 positive regulation of B cell proliferation GO:0030890 9.95 TLR9 TLR4 IL4 IL2 IL13
26 positive regulation of T cell proliferation GO:0042102 9.94 IL4 IL2 IL1B
27 positive regulation of smooth muscle cell proliferation GO:0048661 9.94 TNF IL18 IL13
28 humoral immune response GO:0006959 9.94 TNF LTA IFNG
29 negative regulation of tumor necrosis factor production GO:0032720 9.94 TLR4 IL10 FOXP3
30 positive regulation of interleukin-12 production GO:0032735 9.94 TLR9 TLR4 TLR2 IFNG
31 positive regulation of tumor necrosis factor production GO:0032760 9.93 TLR9 TLR4 TLR2
32 positive regulation of interleukin-10 production GO:0032733 9.93 TLR9 TLR4 TLR2 IL4
33 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.93 TNF IL4 IL2 IL18 IL13 IFNG
34 toll-like receptor signaling pathway GO:0002224 9.92 TLR9 TLR4 TLR2
35 negative regulation of interleukin-6 production GO:0032715 9.92 TNF TLR9 TLR4 IL10 FOXP3
36 negative regulation of endothelial cell apoptotic process GO:2000352 9.91 IL4 IL13 IL10
37 positive regulation of chemokine production GO:0032722 9.91 TNF TLR9 TLR4 TLR2
38 lipopolysaccharide-mediated signaling pathway GO:0031663 9.91 TNF TLR4 TLR2 IL1B IL18
39 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.91 TNF TLR9 TLR4 TLR2 IL1B IL18
40 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.9 IL4 IL2 IL1B
41 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.9 TLR9 TLR4 TLR2
42 positive regulation of cytokine secretion GO:0050715 9.9 TNF IL10 IFNG
43 negative regulation of interferon-gamma production GO:0032689 9.9 TLR4 IL10 FOXP3
44 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.9 TLR9 TLR4 TLR2 IFNG
45 positive regulation of interferon-beta production GO:0032728 9.89 TLR9 TLR4 TLR2
46 positive regulation of chemokine biosynthetic process GO:0045080 9.89 TNF IL4 IL1B IFNG
47 microglial cell activation GO:0001774 9.89 TNF TLR2 IL4 IL13 IFNG
48 positive regulation of glial cell proliferation GO:0060252 9.88 TNF LTA IL1B
49 macrophage activation GO:0042116 9.88 TLR4 SLC11A1 IL4 IL13
50 positive regulation of interleukin-8 production GO:0032757 9.88 TNF TLR9 TLR4 TLR2 IL1B

Molecular functions related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.32 TNF LTA IL4 IL2 IL1B IL18
2 lipopolysaccharide receptor activity GO:0001875 8.96 TLR4 TLR2

Sources for Visceral Leishmaniasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....